nodes	percent_of_prediction	percent_of_DWPC	metapath
Pazopanib—MAP3K9—epithelium—gallbladder cancer	0.0129	0.0422	CbGeAlD
Pazopanib—MAP3K9—pancreas—gallbladder cancer	0.0115	0.0376	CbGeAlD
Pazopanib—PDGFRA—gall bladder—gallbladder cancer	0.00839	0.0275	CbGeAlD
Pazopanib—SH2B3—pancreas—gallbladder cancer	0.00812	0.0266	CbGeAlD
Pazopanib—FGFR3—epithelium—gallbladder cancer	0.00763	0.025	CbGeAlD
Pazopanib—BMPR1B—epithelium—gallbladder cancer	0.00755	0.0247	CbGeAlD
Pazopanib—MAP3K9—liver—gallbladder cancer	0.00731	0.0239	CbGeAlD
Pazopanib—KIT—gall bladder—gallbladder cancer	0.00671	0.022	CbGeAlD
Pazopanib—PDGFRB—gall bladder—gallbladder cancer	0.00655	0.0214	CbGeAlD
Pazopanib—PI4KB—pancreas—gallbladder cancer	0.00601	0.0197	CbGeAlD
Pazopanib—FLT4—epithelium—gallbladder cancer	0.00596	0.0195	CbGeAlD
Pazopanib—MAP3K9—lymph node—gallbladder cancer	0.00561	0.0184	CbGeAlD
Pazopanib—TAOK1—liver—gallbladder cancer	0.00549	0.018	CbGeAlD
Pazopanib—FGF1—epithelium—gallbladder cancer	0.00529	0.0173	CbGeAlD
Pazopanib—PIP4K2C—pancreas—gallbladder cancer	0.00528	0.0173	CbGeAlD
Pazopanib—SH2B3—liver—gallbladder cancer	0.00517	0.0169	CbGeAlD
Pazopanib—FGFR2—epithelium—gallbladder cancer	0.005	0.0164	CbGeAlD
Pazopanib—FLT1—epithelium—gallbladder cancer	0.00463	0.0152	CbGeAlD
Pazopanib—ITK—lymph node—gallbladder cancer	0.00462	0.0151	CbGeAlD
Pazopanib—STK16—liver—gallbladder cancer	0.00439	0.0144	CbGeAlD
Pazopanib—LYN—liver—gallbladder cancer	0.00435	0.0142	CbGeAlD
Pazopanib—RIOK2—liver—gallbladder cancer	0.00433	0.0142	CbGeAlD
Pazopanib—FGFR3—liver—gallbladder cancer	0.00433	0.0142	CbGeAlD
Pazopanib—TAOK1—lymph node—gallbladder cancer	0.00421	0.0138	CbGeAlD
Pazopanib—FLT1—pancreas—gallbladder cancer	0.00412	0.0135	CbGeAlD
Pazopanib—SH2B3—lymph node—gallbladder cancer	0.00396	0.013	CbGeAlD
Pazopanib—KDR—epithelium—gallbladder cancer	0.00391	0.0128	CbGeAlD
Pazopanib—AURKC—lymph node—gallbladder cancer	0.0039	0.0128	CbGeAlD
Pazopanib—TAOK3—pancreas—gallbladder cancer	0.00389	0.0127	CbGeAlD
Pazopanib—STK36—liver—gallbladder cancer	0.00389	0.0127	CbGeAlD
Pazopanib—PI4KB—liver—gallbladder cancer	0.00383	0.0125	CbGeAlD
Pazopanib—LIMK2—liver—gallbladder cancer	0.00376	0.0123	CbGeAlD
Pazopanib—PLK4—lymph node—gallbladder cancer	0.00357	0.0117	CbGeAlD
Pazopanib—KIT—epithelium—gallbladder cancer	0.00347	0.0114	CbGeAlD
Pazopanib—PDGFRB—epithelium—gallbladder cancer	0.00339	0.0111	CbGeAlD
Pazopanib—FLT4—liver—gallbladder cancer	0.00338	0.011	CbGeAlD
Pazopanib—STK16—lymph node—gallbladder cancer	0.00337	0.011	CbGeAlD
Pazopanib—PIP4K2C—liver—gallbladder cancer	0.00336	0.011	CbGeAlD
Pazopanib—FGFR1—liver—gallbladder cancer	0.00333	0.0109	CbGeAlD
Pazopanib—RIOK2—lymph node—gallbladder cancer	0.00332	0.0109	CbGeAlD
Pazopanib—BMPR1B—lymph node—gallbladder cancer	0.00328	0.0107	CbGeAlD
Pazopanib—MAP3K2—liver—gallbladder cancer	0.00318	0.0104	CbGeAlD
Pazopanib—KIT—pancreas—gallbladder cancer	0.00309	0.0101	CbGeAlD
Pazopanib—PDGFRB—pancreas—gallbladder cancer	0.00302	0.00988	CbGeAlD
Pazopanib—FGF1—liver—gallbladder cancer	0.003	0.00981	CbGeAlD
Pazopanib—LCK—liver—gallbladder cancer	0.00298	0.00975	CbGeAlD
Pazopanib—STK36—lymph node—gallbladder cancer	0.00298	0.00975	CbGeAlD
Pazopanib—PI4KB—lymph node—gallbladder cancer	0.00293	0.0096	CbGeAlD
Pazopanib—LIMK2—lymph node—gallbladder cancer	0.00288	0.00943	CbGeAlD
Pazopanib—FGFR2—liver—gallbladder cancer	0.00283	0.00927	CbGeAlD
Pazopanib—FLT1—liver—gallbladder cancer	0.00262	0.00859	CbGeAlD
Pazopanib—FLT4—lymph node—gallbladder cancer	0.00259	0.00847	CbGeAlD
Pazopanib—PIP4K2C—lymph node—gallbladder cancer	0.00257	0.00843	CbGeAlD
Pazopanib—FGFR1—lymph node—gallbladder cancer	0.00255	0.00836	CbGeAlD
Pazopanib—STK10—liver—gallbladder cancer	0.00248	0.00813	CbGeAlD
Pazopanib—TAOK3—liver—gallbladder cancer	0.00247	0.0081	CbGeAlD
Pazopanib—PDGFRA—liver—gallbladder cancer	0.00246	0.00805	CbGeAlD
Pazopanib—MAP3K2—lymph node—gallbladder cancer	0.00244	0.00799	CbGeAlD
Pazopanib—UGT1A1—liver—gallbladder cancer	0.00235	0.00768	CbGeAlD
Pazopanib—FGF1—lymph node—gallbladder cancer	0.0023	0.00753	CbGeAlD
Pazopanib—LCK—lymph node—gallbladder cancer	0.00228	0.00748	CbGeAlD
Pazopanib—KDR—liver—gallbladder cancer	0.00222	0.00726	CbGeAlD
Pazopanib—MAP2K5—liver—gallbladder cancer	0.00222	0.00726	CbGeAlD
Pazopanib—CSF1R—liver—gallbladder cancer	0.00217	0.00709	CbGeAlD
Pazopanib—FLT1—lymph node—gallbladder cancer	0.00201	0.00659	CbGeAlD
Pazopanib—EPHB6—lymph node—gallbladder cancer	0.00199	0.00651	CbGeAlD
Pazopanib—KIT—liver—gallbladder cancer	0.00197	0.00644	CbGeAlD
Pazopanib—SLCO1B1—liver—gallbladder cancer	0.00195	0.00639	CbGeAlD
Pazopanib—PDGFRB—liver—gallbladder cancer	0.00192	0.00629	CbGeAlD
Pazopanib—STK10—lymph node—gallbladder cancer	0.0019	0.00624	CbGeAlD
Pazopanib—TAOK3—lymph node—gallbladder cancer	0.0019	0.00621	CbGeAlD
Pazopanib—PDGFRA—lymph node—gallbladder cancer	0.00189	0.00617	CbGeAlD
Pazopanib—KDR—lymph node—gallbladder cancer	0.0017	0.00557	CbGeAlD
Pazopanib—MAP2K5—lymph node—gallbladder cancer	0.0017	0.00557	CbGeAlD
Pazopanib—CSF1R—lymph node—gallbladder cancer	0.00166	0.00543	CbGeAlD
Pazopanib—KIT—lymph node—gallbladder cancer	0.00151	0.00493	CbGeAlD
Pazopanib—PDGFRB—lymph node—gallbladder cancer	0.00147	0.00482	CbGeAlD
Pazopanib—CYP2C8—liver—gallbladder cancer	0.00111	0.00363	CbGeAlD
Pazopanib—ABCG2—liver—gallbladder cancer	0.00108	0.00353	CbGeAlD
Pazopanib—CYP1A2—liver—gallbladder cancer	0.00104	0.0034	CbGeAlD
Pazopanib—ABCB1—epithelium—gallbladder cancer	0.000939	0.00307	CbGeAlD
Pazopanib—ABCB1—pancreas—gallbladder cancer	0.000836	0.00274	CbGeAlD
Pazopanib—ABCG2—lymph node—gallbladder cancer	0.000828	0.00271	CbGeAlD
Pazopanib—CYP3A4—liver—gallbladder cancer	0.000752	0.00246	CbGeAlD
Pazopanib—CYP2D6—liver—gallbladder cancer	0.00074	0.00242	CbGeAlD
Pazopanib—ABCB1—liver—gallbladder cancer	0.000532	0.00174	CbGeAlD
Pazopanib—ABCB1—lymph node—gallbladder cancer	0.000408	0.00134	CbGeAlD
Pazopanib—FGFR1—Adaptive Immune System—NRAS—gallbladder cancer	7.63e-05	0.00011	CbGpPWpGaD
Pazopanib—KIT—Innate Immune System—EGFR—gallbladder cancer	7.63e-05	0.00011	CbGpPWpGaD
Pazopanib—PDGFRA—Adaptive Immune System—NRAS—gallbladder cancer	7.61e-05	0.00011	CbGpPWpGaD
Pazopanib—FGF1—Innate Immune System—HRAS—gallbladder cancer	7.54e-05	0.000109	CbGpPWpGaD
Pazopanib—LCK—Innate Immune System—ERBB2—gallbladder cancer	7.54e-05	0.000108	CbGpPWpGaD
Pazopanib—LCK—Cytokine Signaling in Immune system—HRAS—gallbladder cancer	7.48e-05	0.000108	CbGpPWpGaD
Pazopanib—LCK—Disease—ERBB4—gallbladder cancer	7.47e-05	0.000108	CbGpPWpGaD
Pazopanib—FLT4—Signaling Pathways—EGFR—gallbladder cancer	7.47e-05	0.000108	CbGpPWpGaD
Pazopanib—FGFR2—Adaptive Immune System—EGFR—gallbladder cancer	7.46e-05	0.000107	CbGpPWpGaD
Pazopanib—LCK—Signaling by NGF—HRAS—gallbladder cancer	7.35e-05	0.000106	CbGpPWpGaD
Pazopanib—FGFR2—Innate Immune System—KRAS—gallbladder cancer	7.34e-05	0.000106	CbGpPWpGaD
Pazopanib—KIT—Adaptive Immune System—EGFR—gallbladder cancer	7.33e-05	0.000106	CbGpPWpGaD
Pazopanib—FGF1—Disease—ERBB2—gallbladder cancer	7.28e-05	0.000105	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—ERBB4—gallbladder cancer	7.26e-05	0.000105	CbGpPWpGaD
Pazopanib—FGFR1—Innate Immune System—EGFR—gallbladder cancer	7.24e-05	0.000104	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—ERBB4—gallbladder cancer	7.24e-05	0.000104	CbGpPWpGaD
Pazopanib—FGF1—Adaptive Immune System—HRAS—gallbladder cancer	7.24e-05	0.000104	CbGpPWpGaD
Pazopanib—LCK—Adaptive Immune System—ERBB2—gallbladder cancer	7.24e-05	0.000104	CbGpPWpGaD
Pazopanib—PDGFRA—Innate Immune System—EGFR—gallbladder cancer	7.22e-05	0.000104	CbGpPWpGaD
Pazopanib—FGFR3—Immune System—NRAS—gallbladder cancer	7.22e-05	0.000104	CbGpPWpGaD
Pazopanib—LYN—Developmental Biology—EGFR—gallbladder cancer	7.21e-05	0.000104	CbGpPWpGaD
Pazopanib—KIT—Innate Immune System—KRAS—gallbladder cancer	7.21e-05	0.000104	CbGpPWpGaD
Pazopanib—PDGFRB—Innate Immune System—NRAS—gallbladder cancer	7.14e-05	0.000103	CbGpPWpGaD
Pazopanib—FLT4—Signaling Pathways—KRAS—gallbladder cancer	7.05e-05	0.000102	CbGpPWpGaD
Pazopanib—FGFR2—Adaptive Immune System—KRAS—gallbladder cancer	7.05e-05	0.000101	CbGpPWpGaD
Pazopanib—LCK—Immune System—ERBB3—gallbladder cancer	7e-05	0.000101	CbGpPWpGaD
Pazopanib—LYN—Innate Immune System—NRAS—gallbladder cancer	6.99e-05	0.000101	CbGpPWpGaD
Pazopanib—FGFR1—Adaptive Immune System—EGFR—gallbladder cancer	6.95e-05	0.0001	CbGpPWpGaD
Pazopanib—PDGFRA—Adaptive Immune System—EGFR—gallbladder cancer	6.94e-05	9.99e-05	CbGpPWpGaD
Pazopanib—KIT—Adaptive Immune System—KRAS—gallbladder cancer	6.92e-05	9.97e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Adaptive Immune System—NRAS—gallbladder cancer	6.86e-05	9.88e-05	CbGpPWpGaD
Pazopanib—BMPR1B—Signaling Pathways—TP53—gallbladder cancer	6.85e-05	9.87e-05	CbGpPWpGaD
Pazopanib—FGFR1—Innate Immune System—KRAS—gallbladder cancer	6.84e-05	9.85e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Innate Immune System—KRAS—gallbladder cancer	6.82e-05	9.83e-05	CbGpPWpGaD
Pazopanib—LYN—Developmental Biology—KRAS—gallbladder cancer	6.82e-05	9.81e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—ERBB3—gallbladder cancer	6.73e-05	9.69e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—BCL2—gallbladder cancer	6.72e-05	9.68e-05	CbGpPWpGaD
Pazopanib—LYN—Adaptive Immune System—NRAS—gallbladder cancer	6.72e-05	9.67e-05	CbGpPWpGaD
Pazopanib—LYN—Hemostasis—KRAS—gallbladder cancer	6.69e-05	9.63e-05	CbGpPWpGaD
Pazopanib—FGFR3—Disease—NRAS—gallbladder cancer	6.67e-05	9.6e-05	CbGpPWpGaD
Pazopanib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—gallbladder cancer	6.62e-05	9.54e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—ERBB3—gallbladder cancer	6.61e-05	9.52e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—BCL2—gallbladder cancer	6.6e-05	9.5e-05	CbGpPWpGaD
Pazopanib—FGFR1—Developmental Biology—HRAS—gallbladder cancer	6.59e-05	9.48e-05	CbGpPWpGaD
Pazopanib—FGFR3—Immune System—EGFR—gallbladder cancer	6.58e-05	9.47e-05	CbGpPWpGaD
Pazopanib—FGFR1—Adaptive Immune System—KRAS—gallbladder cancer	6.57e-05	9.46e-05	CbGpPWpGaD
Pazopanib—BMPR1B—Signaling Pathways—HRAS—gallbladder cancer	6.56e-05	9.44e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Adaptive Immune System—KRAS—gallbladder cancer	6.55e-05	9.44e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—ERBB2—gallbladder cancer	6.53e-05	9.4e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—ERBB4—gallbladder cancer	6.52e-05	9.39e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Innate Immune System—EGFR—gallbladder cancer	6.51e-05	9.37e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—ERBB3—gallbladder cancer	6.46e-05	9.3e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—ERBB2—gallbladder cancer	6.41e-05	9.23e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—ERBB4—gallbladder cancer	6.39e-05	9.2e-05	CbGpPWpGaD
Pazopanib—LYN—Innate Immune System—EGFR—gallbladder cancer	6.37e-05	9.17e-05	CbGpPWpGaD
Pazopanib—LCK—Hemostasis—NRAS—gallbladder cancer	6.37e-05	9.17e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—ERBB3—gallbladder cancer	6.28e-05	9.04e-05	CbGpPWpGaD
Pazopanib—FLT4—Signaling Pathways—TP53—gallbladder cancer	6.27e-05	9.03e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—BCL2—gallbladder cancer	6.26e-05	9.02e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—ERBB3—gallbladder cancer	6.26e-05	9.01e-05	CbGpPWpGaD
Pazopanib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—gallbladder cancer	6.26e-05	9.01e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Adaptive Immune System—EGFR—gallbladder cancer	6.25e-05	9e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—BCL2—gallbladder cancer	6.25e-05	9e-05	CbGpPWpGaD
Pazopanib—FGFR2—Innate Immune System—HRAS—gallbladder cancer	6.24e-05	8.98e-05	CbGpPWpGaD
Pazopanib—FGFR3—Immune System—KRAS—gallbladder cancer	6.22e-05	8.95e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Innate Immune System—KRAS—gallbladder cancer	6.15e-05	8.85e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—ERBB2—gallbladder cancer	6.14e-05	8.84e-05	CbGpPWpGaD
Pazopanib—KIT—Innate Immune System—HRAS—gallbladder cancer	6.13e-05	8.82e-05	CbGpPWpGaD
Pazopanib—LYN—Adaptive Immune System—EGFR—gallbladder cancer	6.12e-05	8.81e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—NRAS—gallbladder cancer	6.11e-05	8.8e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—ERBB2—gallbladder cancer	6.09e-05	8.76e-05	CbGpPWpGaD
Pazopanib—FGFR3—Disease—EGFR—gallbladder cancer	6.08e-05	8.75e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—ERBB2—gallbladder cancer	6.07e-05	8.74e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—ERBB2—gallbladder cancer	6.03e-05	8.68e-05	CbGpPWpGaD
Pazopanib—LYN—Innate Immune System—KRAS—gallbladder cancer	6.02e-05	8.67e-05	CbGpPWpGaD
Pazopanib—FGF1—Immune System—NRAS—gallbladder cancer	6e-05	8.64e-05	CbGpPWpGaD
Pazopanib—FLT4—Signaling Pathways—HRAS—gallbladder cancer	6e-05	8.63e-05	CbGpPWpGaD
Pazopanib—FGFR2—Adaptive Immune System—HRAS—gallbladder cancer	5.99e-05	8.63e-05	CbGpPWpGaD
Pazopanib—LYN—Hemostasis—TP53—gallbladder cancer	5.94e-05	8.56e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—ERBB2—gallbladder cancer	5.92e-05	8.52e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Adaptive Immune System—KRAS—gallbladder cancer	5.9e-05	8.5e-05	CbGpPWpGaD
Pazopanib—KIT—Adaptive Immune System—HRAS—gallbladder cancer	5.88e-05	8.47e-05	CbGpPWpGaD
Pazopanib—FGFR1—Innate Immune System—HRAS—gallbladder cancer	5.82e-05	8.37e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Innate Immune System—HRAS—gallbladder cancer	5.8e-05	8.35e-05	CbGpPWpGaD
Pazopanib—LYN—Developmental Biology—HRAS—gallbladder cancer	5.79e-05	8.34e-05	CbGpPWpGaD
Pazopanib—LYN—Adaptive Immune System—KRAS—gallbladder cancer	5.78e-05	8.32e-05	CbGpPWpGaD
Pazopanib—FGFR3—Disease—KRAS—gallbladder cancer	5.74e-05	8.26e-05	CbGpPWpGaD
Pazopanib—LCK—Innate Immune System—NRAS—gallbladder cancer	5.73e-05	8.25e-05	CbGpPWpGaD
Pazopanib—LYN—Hemostasis—HRAS—gallbladder cancer	5.68e-05	8.18e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—ERBB3—gallbladder cancer	5.64e-05	8.12e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—BCL2—gallbladder cancer	5.63e-05	8.11e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—ERBB2—gallbladder cancer	5.62e-05	8.09e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—ERBB2—gallbladder cancer	5.6e-05	8.07e-05	CbGpPWpGaD
Pazopanib—FGFR1—Adaptive Immune System—HRAS—gallbladder cancer	5.58e-05	8.04e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—EGFR—gallbladder cancer	5.57e-05	8.02e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Adaptive Immune System—HRAS—gallbladder cancer	5.57e-05	8.02e-05	CbGpPWpGaD
Pazopanib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—gallbladder cancer	5.56e-05	8.01e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—NRAS—gallbladder cancer	5.54e-05	7.98e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—ERBB3—gallbladder cancer	5.52e-05	7.95e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—BCL2—gallbladder cancer	5.51e-05	7.94e-05	CbGpPWpGaD
Pazopanib—LCK—Adaptive Immune System—NRAS—gallbladder cancer	5.5e-05	7.93e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—ERBB2—gallbladder cancer	5.49e-05	7.9e-05	CbGpPWpGaD
Pazopanib—LCK—Hemostasis—KRAS—gallbladder cancer	5.48e-05	7.89e-05	CbGpPWpGaD
Pazopanib—FGF1—Immune System—EGFR—gallbladder cancer	5.47e-05	7.87e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—ERBB2—gallbladder cancer	5.47e-05	7.87e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—ERBB2—gallbladder cancer	5.35e-05	7.71e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—ERBB2—gallbladder cancer	5.35e-05	7.7e-05	CbGpPWpGaD
Pazopanib—FGFR3—Immune System—HRAS—gallbladder cancer	5.28e-05	7.61e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—KRAS—gallbladder cancer	5.26e-05	7.58e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—ERBB4—gallbladder cancer	5.23e-05	7.54e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Innate Immune System—HRAS—gallbladder cancer	5.23e-05	7.52e-05	CbGpPWpGaD
Pazopanib—LCK—Innate Immune System—EGFR—gallbladder cancer	5.22e-05	7.52e-05	CbGpPWpGaD
Pazopanib—FGF1—Immune System—KRAS—gallbladder cancer	5.17e-05	7.44e-05	CbGpPWpGaD
Pazopanib—LYN—Innate Immune System—HRAS—gallbladder cancer	5.12e-05	7.37e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—ERBB2—gallbladder cancer	5.1e-05	7.34e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—EGFR—gallbladder cancer	5.05e-05	7.27e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—ERBB2—gallbladder cancer	5.05e-05	7.27e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Adaptive Immune System—HRAS—gallbladder cancer	5.02e-05	7.23e-05	CbGpPWpGaD
Pazopanib—LCK—Adaptive Immune System—EGFR—gallbladder cancer	5.02e-05	7.22e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—NRAS—gallbladder cancer	4.97e-05	7.15e-05	CbGpPWpGaD
Pazopanib—LCK—Innate Immune System—KRAS—gallbladder cancer	4.93e-05	7.1e-05	CbGpPWpGaD
Pazopanib—LYN—Adaptive Immune System—HRAS—gallbladder cancer	4.91e-05	7.07e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—NRAS—gallbladder cancer	4.88e-05	7.02e-05	CbGpPWpGaD
Pazopanib—FGFR3—Disease—HRAS—gallbladder cancer	4.88e-05	7.02e-05	CbGpPWpGaD
Pazopanib—LCK—Hemostasis—TP53—gallbladder cancer	4.87e-05	7.01e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—KRAS—gallbladder cancer	4.77e-05	6.87e-05	CbGpPWpGaD
Pazopanib—LCK—Adaptive Immune System—KRAS—gallbladder cancer	4.74e-05	6.82e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—TP53—gallbladder cancer	4.68e-05	6.73e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—NRAS—gallbladder cancer	4.67e-05	6.72e-05	CbGpPWpGaD
Pazopanib—LCK—Hemostasis—HRAS—gallbladder cancer	4.66e-05	6.71e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—NRAS—gallbladder cancer	4.63e-05	6.67e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—NRAS—gallbladder cancer	4.62e-05	6.65e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—NRAS—gallbladder cancer	4.59e-05	6.6e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—EGFR—gallbladder cancer	4.53e-05	6.52e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—ERBB3—gallbladder cancer	4.53e-05	6.52e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—BCL2—gallbladder cancer	4.52e-05	6.5e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—NRAS—gallbladder cancer	4.5e-05	6.49e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—HRAS—gallbladder cancer	4.47e-05	6.44e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—EGFR—gallbladder cancer	4.44e-05	6.4e-05	CbGpPWpGaD
Pazopanib—FGF1—Immune System—HRAS—gallbladder cancer	4.39e-05	6.32e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—ERBB2—gallbladder cancer	4.39e-05	6.32e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—KRAS—gallbladder cancer	4.28e-05	6.16e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—NRAS—gallbladder cancer	4.27e-05	6.16e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—NRAS—gallbladder cancer	4.26e-05	6.14e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—EGFR—gallbladder cancer	4.25e-05	6.13e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—ERBB2—gallbladder cancer	4.22e-05	6.08e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—EGFR—gallbladder cancer	4.22e-05	6.07e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—EGFR—gallbladder cancer	4.21e-05	6.06e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—KRAS—gallbladder cancer	4.2e-05	6.05e-05	CbGpPWpGaD
Pazopanib—LCK—Innate Immune System—HRAS—gallbladder cancer	4.19e-05	6.04e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—EGFR—gallbladder cancer	4.18e-05	6.02e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—NRAS—gallbladder cancer	4.17e-05	6.01e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—NRAS—gallbladder cancer	4.16e-05	5.99e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—ERBB2—gallbladder cancer	4.15e-05	5.97e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—EGFR—gallbladder cancer	4.1e-05	5.91e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—NRAS—gallbladder cancer	4.07e-05	5.87e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—NRAS—gallbladder cancer	4.07e-05	5.86e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—HRAS—gallbladder cancer	4.05e-05	5.84e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—ERBB2—gallbladder cancer	4.05e-05	5.83e-05	CbGpPWpGaD
Pazopanib—LCK—Adaptive Immune System—HRAS—gallbladder cancer	4.03e-05	5.8e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—KRAS—gallbladder cancer	4.02e-05	5.79e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—KRAS—gallbladder cancer	3.99e-05	5.74e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—KRAS—gallbladder cancer	3.97e-05	5.72e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—KRAS—gallbladder cancer	3.95e-05	5.68e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—ERBB2—gallbladder cancer	3.93e-05	5.67e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—ERBB2—gallbladder cancer	3.92e-05	5.65e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—EGFR—gallbladder cancer	3.89e-05	5.61e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—EGFR—gallbladder cancer	3.88e-05	5.59e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—NRAS—gallbladder cancer	3.88e-05	5.59e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—KRAS—gallbladder cancer	3.88e-05	5.58e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—NRAS—gallbladder cancer	3.84e-05	5.53e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—EGFR—gallbladder cancer	3.8e-05	5.48e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—EGFR—gallbladder cancer	3.79e-05	5.46e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—EGFR—gallbladder cancer	3.71e-05	5.34e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—EGFR—gallbladder cancer	3.71e-05	5.34e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—KRAS—gallbladder cancer	3.68e-05	5.3e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—KRAS—gallbladder cancer	3.67e-05	5.28e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—HRAS—gallbladder cancer	3.63e-05	5.23e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—KRAS—gallbladder cancer	3.59e-05	5.17e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—KRAS—gallbladder cancer	3.58e-05	5.16e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—TP53—gallbladder cancer	3.57e-05	5.14e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—HRAS—gallbladder cancer	3.57e-05	5.14e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—EGFR—gallbladder cancer	3.54e-05	5.09e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—ERBB2—gallbladder cancer	3.54e-05	5.09e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—KRAS—gallbladder cancer	3.51e-05	5.05e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—KRAS—gallbladder cancer	3.5e-05	5.04e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—EGFR—gallbladder cancer	3.5e-05	5.04e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—ERBB2—gallbladder cancer	3.46e-05	4.98e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—HRAS—gallbladder cancer	3.42e-05	4.92e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—HRAS—gallbladder cancer	3.39e-05	4.88e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—HRAS—gallbladder cancer	3.38e-05	4.86e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—HRAS—gallbladder cancer	3.36e-05	4.83e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—KRAS—gallbladder cancer	3.34e-05	4.81e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—NRAS—gallbladder cancer	3.34e-05	4.81e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—KRAS—gallbladder cancer	3.31e-05	4.76e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—HRAS—gallbladder cancer	3.3e-05	4.74e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—NRAS—gallbladder cancer	3.21e-05	4.62e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—TP53—gallbladder cancer	3.19e-05	4.6e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—NRAS—gallbladder cancer	3.15e-05	4.54e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—HRAS—gallbladder cancer	3.13e-05	4.5e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—HRAS—gallbladder cancer	3.12e-05	4.49e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—TP53—gallbladder cancer	3.11e-05	4.48e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—NRAS—gallbladder cancer	3.08e-05	4.44e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—HRAS—gallbladder cancer	3.05e-05	4.4e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—HRAS—gallbladder cancer	3.04e-05	4.38e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—EGFR—gallbladder cancer	3.04e-05	4.38e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—NRAS—gallbladder cancer	2.99e-05	4.31e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—NRAS—gallbladder cancer	2.99e-05	4.3e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—HRAS—gallbladder cancer	2.98e-05	4.29e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—HRAS—gallbladder cancer	2.98e-05	4.29e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—TP53—gallbladder cancer	2.97e-05	4.27e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—EGFR—gallbladder cancer	2.93e-05	4.21e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—EGFR—gallbladder cancer	2.87e-05	4.14e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—KRAS—gallbladder cancer	2.87e-05	4.14e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—HRAS—gallbladder cancer	2.84e-05	4.09e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—ERBB2—gallbladder cancer	2.84e-05	4.09e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—HRAS—gallbladder cancer	2.81e-05	4.05e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—EGFR—gallbladder cancer	2.81e-05	4.04e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—KRAS—gallbladder cancer	2.76e-05	3.98e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—EGFR—gallbladder cancer	2.73e-05	3.93e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—EGFR—gallbladder cancer	2.72e-05	3.92e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—KRAS—gallbladder cancer	2.71e-05	3.91e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—NRAS—gallbladder cancer	2.69e-05	3.87e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—KRAS—gallbladder cancer	2.65e-05	3.82e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—NRAS—gallbladder cancer	2.63e-05	3.79e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—KRAS—gallbladder cancer	2.58e-05	3.71e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—KRAS—gallbladder cancer	2.57e-05	3.7e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—TP53—gallbladder cancer	2.46e-05	3.54e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—EGFR—gallbladder cancer	2.45e-05	3.53e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—HRAS—gallbladder cancer	2.44e-05	3.52e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—TP53—gallbladder cancer	2.41e-05	3.47e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—EGFR—gallbladder cancer	2.4e-05	3.45e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—HRAS—gallbladder cancer	2.35e-05	3.38e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—KRAS—gallbladder cancer	2.32e-05	3.33e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—HRAS—gallbladder cancer	2.31e-05	3.32e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—TP53—gallbladder cancer	2.29e-05	3.3e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—TP53—gallbladder cancer	2.28e-05	3.29e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—KRAS—gallbladder cancer	2.27e-05	3.26e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—HRAS—gallbladder cancer	2.26e-05	3.25e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—HRAS—gallbladder cancer	2.19e-05	3.15e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—HRAS—gallbladder cancer	2.18e-05	3.15e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—NRAS—gallbladder cancer	2.16e-05	3.11e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—TP53—gallbladder cancer	2.06e-05	2.96e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—TP53—gallbladder cancer	2.01e-05	2.9e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—HRAS—gallbladder cancer	1.97e-05	2.83e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—EGFR—gallbladder cancer	1.97e-05	2.83e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—HRAS—gallbladder cancer	1.93e-05	2.77e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—KRAS—gallbladder cancer	1.86e-05	2.68e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—TP53—gallbladder cancer	1.65e-05	2.38e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—HRAS—gallbladder cancer	1.58e-05	2.27e-05	CbGpPWpGaD
